利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14485 条记录 (耗时 0.016 秒)

    FCRN ANTIBODIES AND METHODS OF USE THEREOF
    6.
    发明申请
    FCRN ANTIBODIES AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2019118791A1

    公开(公告)日：2019-06-20

    申请号：PCT/US2018/065568

    申请日：2018-12-13

    申请人： MOMENTA PHARMACEUTICALS, INC.

    发明人： HILLSON, Jan

    IPC分类号： A61K39/395 ,  C07K16/28 ,  A61P37/00

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K2039/505 ,  A61P37/00 ,  C07K2317/565

    摘要： The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

    PD1 POLYPEPTIDE BINDING MOLECULES
    8.
    发明申请
    PD1 POLYPEPTIDE BINDING MOLECULES 审中-公开

    公开(公告)号：WO2019094265A1

    公开(公告)日：2019-05-16

    申请号：PCT/US2018/058824

    申请日：2018-11-02

    申请人： ARMO BIOSCIENCES, INC.

    发明人： MCCAULEY, Scott

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28

    CPC分类号： C07K16/2818 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present disclosure provides polypeptide binding molecules that bind to Programmed Cell Death-1 (PD-1) and inhibit PD-1 interaction with both Programmed Cell Death Ligand-1 (PD-L1) and/or Programmed Cell Death Ligand-2 (PD-L2). The present disclosure further provides pharmaceutical formulations comprising the molecules of the present invention. The present disclosure further provides methods of use of such polypeptide binding molecules in the treatment of various disorders and diseases. The present disclosure further provides recombinant nucleic acid sequences encoding such polypeptide binding molecules and cells transformed therewith. The present disclosure also provides methods of use of the molecules of the present invention in the diagnosis, prevention and treatment of various disorders or conditions in subjects including but not limited to the treatment of neoplastic disorders including but not limited to cancer.